Astatine-211 (At-211) is one of a handful of promising alpha emitting radioisotopes for cancer therapy. Its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to ...

Researchers in Japan are developing world-leading expertise in making and using the alpha particle emitter, astatine-211 (211 At), which has potential for use as a strong radionuclide therapy for ...

France’s Framatome and IBA (Ion Beam Applications, Euronext), a specialist in particle accelerator technology and ...